U.S. loses measles elimination status; SAINT trial finds no rise in vaginal birth with hyoscine or bicarbonate; biomarkers guide preeclampsia delivery

Listen to this post
read by AI voices · all episodesThe Pan American Health Organization (PAHO) said Nov. 17 that the U.S. had lost measles elimination status, and the American College of Obstetricians and Gynecologists (ACOG) urged MMR vaccination before pregnancy. A Norwegian trial found neither hyoscine butylbromide nor sodium bicarbonate raised spontaneous vaginal birth after induction, and a cohort study tied biomarker-guided delivery to less severe preeclampsia.
- Public health Nov 17, 2026Pan American Health Organization Director Jarbas Barbosa said at a Nov. 17 briefing that the U.S. had lost measles elimination status, confirming earlier Wall Street Journal reports, according to Contagion Live. The Centers for Disease Control and Prevention (CDC) counted 5,838 confirmed U.S. cases in 2026 as of Nov. 19. Dr. Camille A. Clare, president of the American College of Obstetricians and Gynecologists, said MMR vaccination before pregnancy offers the best protection and exposed nonimmune pregnant patients should receive immune globulin within six days.
- Research Nov 18, 2026In the phase 3, double-blind, 2-by-2 factorial SAINT trial at 11 Norwegian hospitals, published Nov. 18 in The BMJ, 3,094 nulliparous women having induction of labor were randomized to oral sodium bicarbonate, intravenous hyoscine butylbromide, both or double placebo. Spontaneous vaginal birth, the primary outcome, occurred in 57% with both drugs, 61% with bicarbonate, 61% with hyoscine butylbromide and 56% with placebo; no difference versus placebo was significant (hyoscine butylbromide 4.0 percentage points, 95% CI -0.8 to 8.9; P = .10). The authors said the findings do not support routine intrapartum use of either agent.
- Research Nov 21, 2026A before-after cohort study at two centers, published Nov. 21 in the American Journal of Obstetrics & Gynecology, compared women with preeclampsia without severe features at 34+0 to 36+6 weeks managed expectantly in 2014 to 2017 with women managed by angiogenic biomarkers in 2022 to 2025, with delivery recommended for an abnormal profile. Progression to preeclampsia with severe features fell from 52.1% to 19.6% (adjusted odds ratio 0.22, 95% CI 0.13 to 0.38), without earlier delivery (36.7 versus 36.6 weeks). Composite neonatal morbidity fell from 57.0% to 45.6%, driven by fewer neonatal admissions.
- Research Nov 17, 2026In a double-blind, placebo-controlled trial at nine U.S. sites, published Nov. 17 in Obstetrics & Gynecology, 201 women with vulvar lichen sclerosus having three fractionated carbon dioxide laser treatments were randomized to clobetasol propionate 0.05% or placebo ointment. The primary outcome, an improvement of 16 or more points on the Skindex-29, was reached by 30.3% with clobetasol versus 27.5% with placebo (P = .67). The clobetasol group had greater improvement in Skindex-29 symptom scores (P < .01) and more were satisfied or very satisfied (85.4% versus 69.2%, P = .01).Sources: Obstetrics & Gynecology, PubMed
The weekly innovation roundup for obstetrics and gynecology, published every Sunday for the week before; every item links to its sources. Latest obstetrics and gynecology news · All specialties